|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | AHA/ASA关于卒中和短暂性脑缺血发作患者卒中预防推荐的更新显示文摘在卒中和短暂性脑缺血发作(transient ischemic attack,TIA)患者卒中预防推荐发表以后,美国心脏协会和美国卒中协会(American Heart Association/American Stroke Association,AHA/ASA)著述委员会对最近的一些试验结果进行了回顾。本文的目的是对这些新资料做简要回顾、更新某些推荐意见并说明进行这些修改的理由。在2个领域已发表了一些新的重要临床试验结果:(1)在非心源性栓塞所致缺血性卒中或TIA患者卒中二级预防中具体抗血小板药的应用;(2)他汀类药物在预防卒中复发中的应用。 | Robert J. Adams Greg Albers Mark J. Alberts Oscar Benavente Karen Furie Larry B. Goldstein Philip Gorelick Jonathan Halperin Robert Harbaugh S. Claiborne Johnston Irene Katzan Margaret Kelly-Hayes Edgar J. Kenton Michael Marks Ralph L. Sacco Lee H. Schwamm 赵洪芹 李海峰 (译) | 2008 | 国际脑血管病杂志2008，16，4： | 123 |
| 2 | 卒中或短暂性脑缺血发作患者的卒中预防指南 美国心脏协会/美国卒中协会为医疗卫生专业人员制定的指南显示文摘本指南旨在为缺血性卒中或短暂性脑缺血发作存活患者的卒中预防提供全面和及时的循证推荐,包括危险因素的控制、动脉粥样硬化性疾病的于预、心源性栓塞的抗栓治疗以及非心源性栓塞性卒中的抗血小板治疗。另外,还对其他许多特殊情况下的复发性卒中预防提供了推荐意见,包括动脉夹层分离、卯圆孔未闭、高同型半胱氨酸血症、高凝状态、镰状细胞病、脑静脉窦血栓形成、女性卒中(尤其是与妊娠和绝经后雌激素替代治疗相关性卒中)、脑出血后抗凝药的使用等,以及实施本指南及其在高危人群中应用的特定方法。 | Karen L. Furie Scott E. Kasner Robert J. Adams Gregory W. Albers Ruth L. Bush Susan C. Fagan Jonathan L. Halperin S. Claiborne Johnston Irene Katzan Walter N. Kernan Pamela H. Mitchell Bruce Ovbiagele Yuko Y. Palesch Ralph L. Sacco Lee H. Schwamm Sylvia Wassertheil-Smoller Tanya N. Turan Deidre Wentworth 李海峰(译) 刘涛(译) 杨潘(译) 王鹏(译) | 2011 | 国际脑血管病杂志2011，19，1： | 391 |
| 3 | Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association显示文摘 | Karen L. Furie Scott E. Kasner Robert J. Adams Gregory W. Albers Ruth L. Bush Susan C. Fagan Jonathan L. Halperin S. Claiborne Johnston Irene Katzan Walter N. Kernan Pamela H. Mitchell Bruce Ovbiagele Yuko Y. Palesch Ralph L. Sacco Lee H. Schwamm Sylvia W | 2011 | Stroke2011，，1： | 8 |
| 4 | 胰岛素抵抗者的葡萄糖刺激胰岛素分泌的增强作用受损显示文摘T2DM根据IR和胰岛p细胞功能障碍进行分类,后者可能是胰岛B细胞胰岛素信号缺陷引起的。为评估IR人群较之胰岛素敏感人群在胰岛素调节葡萄糖刺激的胰岛素分泌(GSIS)方面的作用,美国研究者对10例IGT患者. | Halperin F Lopez X Manning R | 2014 | 中国糖尿病杂志2014，22，1： | 4 |
| 5 | 缺血性卒中或短暂性脑缺血发作患者的卒中预防指南显示文摘这份新声明旨在为缺血性卒中或短暂性脑缺血发作存活者的缺血性卒中预防提供全面和及时的循证推荐,循证推荐包括对危险因素的控制,动脉粥样硬化性疾病的干预措施,心源性栓塞的抗栓治疗以及非心源性卒中抗血小板药的应用。另外,还为其他多种特殊情况下复发性卒中的预防提供了推荐、包括动脉夹层分离、卵圆孔未闭、高同型半胱氨酸血症、高凝状态、镰状细胞病、脑静脉窦血栓形成、女性卒中(特别是与妊娠和绝经后激素替代治疗相关卒中),脑出血后肮凝药的应用,以及该指南在高危人群中执行和应用的特殊措施。 | Ralph L.Sacco Robert Adams Grge Albers Mark J.ALBERTS Oscar Benavente Karen Furie Larry B.Goldstein Philip Gorelick Jonathan Halperin Robert Harbaugh S.Claiborne Johnston Irene Katzan Margaret Kelly-Hayes Edgar J.Kenton Michael Marks Lee H.Schwamm Thomas Tomsick 曹勇军(译) 陈孝东(译) 毛成洁(译) 刘春风(译) | 2006 | 中华脑血管病论坛2006，4，1： | 3 |
| 6 | Sympathetic skin response:a method of assessing unmyelinated axon dysfunction in peripheral neuropathies显示文摘 | Shahani BT Halperin JJ Boulu P | 1984 | J Neurol Neurosurg Psychiatry1984，47，5： | 2 |
| 7 | Analytical and experimental investigation of laser-textured mechanical seal faces 显示文摘 | Etsion I Kligerman Y Halperin G | 1999 | Tribology Transactions1999，42，3： | 2 |
| 8 | Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association显示文摘 | Karen L. Furie Scott E. Kasner Robert J. Adams Gregory W. Albers Ruth L. Bush Susan C. Fagan Jonathan L. Halperin S. Claiborne Johnston Irene Katzan Walter N. Kernan Pamela H. Mitchell Bruce Ovbiagele Yuko Y. Palesch Ralph L. Sacco Lee H. Schwamm Sylvia W | 2011 | Stroke2011，，1： | 2 |
| 9 | 2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline)显示文摘 | Thom W. Rooke Alan T. Hirsch Sanjay Misra Anton N. Sidawy Joshua A. Beckman Laura K. Findeiss Jafar Golzarian Heather L. Gornik Jonathan L. Halperin Michael R. Jaff Gregory L. Moneta Jeffrey W. Olin James C. Stanley Christopher J. White John V. White R. E | 2011 | Journal of the American College of Cardiology2011，，： | 2 |
| 10 | Improved scoring system for the electrocardiographic diagnosis of left ventricular hypertrophy显示文摘BACKGROUND Left ventricular hypertrophy(LVH) is a common manifestation of cardiovascular disease and a risk factor for cardiovascular morbidity and mortality, but available methods for its electrocardiographic(ECG) diagnosis have limited accuracy.AIM To investigate findings associated with LVH on ECG and developed an improved system for the diagnosis of LVH.METHODS A cohort study comparing ECG data acquired within 30 days of transthoracic echocardiography(TTE) was performed. Multivariate regression analysis identified ECG findings associated with increased LV mass and mass index. A scoring system was derived and performance compared to established criteria for LVH.RESULTS Data from 5486 outpatients with TTEs and corresponding ECGs were included in the derivation cohort, 333(6.1%) of whom had LVH by TTE. In the primary regression analysis, findings associated with LVH were amplitudes of Q in V3, R in V6, S in V3, T in V6, P' in V1, P in V6, as well as R and T-axis discordance, R peak time in V6, QRS duration, weight, height, sex, and age. From this we derived a score consisting of 5 criteria, and validated it in an independent cohort of 910 patients. With a threshold of 1.5 points, sensitivity and specificity were67.9% and 81.4%, and 62.5% and 83.2% in the derivation and validation cohorts,respectively. With a threshold of 2 points, sensitivity and specificity were 42.3% and 93.0%, and 37.5% and 93.4% in these cohorts.CONCLUSIONS This score had superior sensitivity for detection of LVH by ECG while making a modest sacrifice in specificity compared to conventional criteria. | Eric D Braunstein Lori B Croft Jonathan L Halperin Steve L Liao | 2019 | World Journal of Cardiology2019，11，3： | 2 |
| 11 | Evidence-based guideline: Treatment of parenchymal neurocysticercosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology显示文摘 | Ruth Ann Baird Sam Wiebe Joseph R. Zunt John J. Halperin Gary Gronseth Karen L. Roos | 2013 | Neurology2013，，15： | 2 |
| 12 | Tumor microRNA-29a expression and the risk of recurrence in stage IIcolon cancer显示文摘 | Alina Weissmann-Brenner Michal Kushnir Gila Lithwick Yanai Ranit Aharonov Hadas Gibori Ofer Purim Yulia Kundel Sara Morgenstern Marissa Halperin Yaron Niv Baruch Brenner | 2012 | International Journal of Oncology2012，，： | 2 |
| 13 | Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial显示文摘Background:The Ad5-nCoV vaccine is a single-dose adenovirus type 5(Ad5)vectored vaccine expressing the SARS-CoV2 spike protein that was well-tolerated and immunogenic in phase 1 and 2 studies.In this study,we report results on the final efficacy and interim safety analyses of the phase 3 trial.Methods:This double-blind,randomised,international,placebo-controlled,endpoint-case driven,phase 3,clinical trial enrolled adults aged 18 years older at study centres in Argentina,Chile,Mexico,Pakistan,and Russia.Participants were eligible for the study if they had no unstable or severe underlying medical or psychiatric conditions;had no history of a laboratoryconfirmed SARS-CoV-2 infection;were not pregnant or breastfeeding;and had no previous receipt of an adenovirus-vectored,coronavirus,or SARS-CoV-2 vaccine.After informed consent was obtained,25 mL of whole blood was withdrawn from all eligible participants who were randomised in a 1:1 ratio to receive a single intramuscular dose of 0·5 mL placebo or a 0·5 mL dose of 5×1010 viral particle(vp)/mL Ad5-nCoV vaccine;study staff and participants were blinded to treatment allocation.All participants were contacted weekly by email,telephone,or text message to self-report any symptoms of COVID-19 illness,and laboratory testing for SARS-CoV-2 was done for all participants with any symptoms.The primary efficacy objective evaluated Ad5-nCoV in preventing symptomatic,PCR-confirmed COVID-19 infection occurring at least 28 days after vaccination in all participants who were at least 28 days postvaccination on Jan 15,2021.The primary safety objective evaluated the incidence of any serious adverse events or medically attended adverse events postvaccination in all participants who received a study injection.This trial is closed for enrolment and is registered with ClinicalTrials.gov(NCT04526990). | Scott A Halperin | 2021 | 四川生理科学杂志2021，43，10： | 2 |
| 14 | A Laser Surface Textured Hydrostatic Mechanical Seal 显示文摘 | I Etsion G Halperin | 2002 | Tribology Transactions2002，45，3： | 1 |
| 15 | Anti-inflammatory effects of moxifloxacin on IL-8, IL-1beta and TNF-alpha secretion and NFkappaB and MAP-kinase activation in human monoeytes stimulated with Aspergillus fumigatus 显示文摘 | Shalit I Halperin D Haite D | 2006 | J Araimicrob Chemother2006，57，2： | 1 |
| 16 | Analytical and experimental investigation of laser-textured mechanical seal faces显示文摘 | Etsion I Ktigerman Y Halperin G | 1999 | Tribology Transactions1999，42，3： | 1 |
| 17 | Cold and hot denaturation ofpolysoaps显示文摘 | Leckband D E Borisov 0 V Halperin A | 1998 | Macromolecules1998，31，7： | 1 |
| 18 | Analytical and Experimental Investigation of Laser-Textured Mechanical Seal Faces显示文摘 | Etsion I Kligerman Y Halperin G | 1999 | Tribology Transactions1999，42，3： | 1 |
| 19 | Parity effects in small superconducting particles 显示文摘 | Berger S D Halperin B I | 1998 | Phys Rev B1998，58，： | 1 |
| 20 | ~(125)I embedded in an orbital prosthesis for retreatment of recurrent retinoblastoma 显示文摘 | Bentel GC Halperin EC Buckley EG | 1993 | Med Dosim1993，18，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员